🚀 VC round data is live in beta, check it out!
Oxford BioMedica Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oxford BioMedica and similar public comparables like Fortrea, R&G PharmaStudies, Gubra, Akums Drugs and Pharma and more.
Oxford BioMedica Overview
About Oxford BioMedica
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types.
Founded
1996
HQ
Employees
861
Website
Financials (LTM)
EV
$1B
Oxford BioMedica Financials
Oxford BioMedica reported last 12-month revenue of $251M and EBITDA of $12M.
In the same LTM period, Oxford BioMedica generated $108M in gross profit, $12M in EBITDA, and had net loss of ($33M).
Revenue (LTM)
Oxford BioMedica P&L
In the most recent fiscal year, Oxford BioMedica reported revenue of $228M and EBITDA of $3M.
Oxford BioMedica expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $251M | XXX | $228M | XXX | XXX | XXX |
| Gross Profit | $108M | XXX | $89M | XXX | XXX | XXX |
| Gross Margin | 43% | XXX | 39% | XXX | XXX | XXX |
| EBITDA | $12M | XXX | $3M | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 1% | XXX | XXX | XXX |
| EBIT Margin | (10%) | XXX | (15%) | XXX | XXX | XXX |
| Net Profit | ($33M) | XXX | ($41M) | XXX | XXX | XXX |
| Net Margin | (13%) | XXX | (18%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oxford BioMedica Stock Performance
Oxford BioMedica has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Oxford BioMedica's stock price is $8.39.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -0.5% | XXX | XXX | XXX | $-0.34 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOxford BioMedica Valuation Multiples
Oxford BioMedica trades at 4.3x EV/Revenue multiple, and 91.9x EV/EBITDA.
EV / Revenue (LTM)
Oxford BioMedica Financial Valuation Multiples
As of April 18, 2026, Oxford BioMedica has market cap of $1B and EV of $1B.
Equity research analysts estimate Oxford BioMedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oxford BioMedica has a P/E ratio of (30.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBITDA | 91.9x | XXX | 332.0x | XXX | XXX | XXX |
| EV/EBIT | (42.8x) | XXX | (32.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 10.0x | XXX | 12.1x | XXX | XXX | XXX |
| P/E | (30.9x) | XXX | (24.9x) | XXX | XXX | XXX |
| EV/FCF | (50.1x) | XXX | (188.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oxford BioMedica Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oxford BioMedica Margins & Growth Rates
Oxford BioMedica's revenue in the last 12 month grew by 34%.
Oxford BioMedica's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Oxford BioMedica's rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oxford BioMedica's rule of X is 101% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Oxford BioMedica Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Growth | 285% | XXX | 898% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 47% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 101% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 21% | XXX | 22% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oxford BioMedica Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Oxford BioMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Fortrea | XXX | XXX | XXX | XXX | XXX | XXX |
| R&G PharmaStudies | XXX | XXX | XXX | XXX | XXX | XXX |
| Gubra | XXX | XXX | XXX | XXX | XXX | XXX |
| Akums Drugs and Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Evotec | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oxford BioMedica M&A Activity
Oxford BioMedica acquired XXX companies to date.
Last acquisition by Oxford BioMedica was on XXXXXXXX, XXXXX. Oxford BioMedica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oxford BioMedica
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOxford BioMedica Investment Activity
Oxford BioMedica invested in XXX companies to date.
Oxford BioMedica made its latest investment on XXXXXXXX, XXXXX. Oxford BioMedica invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oxford BioMedica
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oxford BioMedica
| When was Oxford BioMedica founded? | Oxford BioMedica was founded in 1996. |
| Where is Oxford BioMedica headquartered? | Oxford BioMedica is headquartered in United Kingdom. |
| How many employees does Oxford BioMedica have? | As of today, Oxford BioMedica has over 861 employees. |
| Who is the CEO of Oxford BioMedica? | Oxford BioMedica's CEO is Frank Mathias. |
| Is Oxford BioMedica publicly listed? | Yes, Oxford BioMedica is a public company listed on London Stock Exchange. |
| What is the stock symbol of Oxford BioMedica? | Oxford BioMedica trades under OXB ticker. |
| When did Oxford BioMedica go public? | Oxford BioMedica went public in 2001. |
| Who are competitors of Oxford BioMedica? | Oxford BioMedica main competitors are Fortrea, R&G PharmaStudies, Gubra, Akums Drugs and Pharma. |
| What is the current market cap of Oxford BioMedica? | Oxford BioMedica's current market cap is $1B. |
| What is the current revenue of Oxford BioMedica? | Oxford BioMedica's last 12 months revenue is $251M. |
| What is the current revenue growth of Oxford BioMedica? | Oxford BioMedica revenue growth (NTM/LTM) is 34%. |
| What is the current EV/Revenue multiple of Oxford BioMedica? | Current revenue multiple of Oxford BioMedica is 4.3x. |
| Is Oxford BioMedica profitable? | Yes, Oxford BioMedica is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Oxford BioMedica? | Oxford BioMedica's last 12 months EBITDA is $12M. |
| What is Oxford BioMedica's EBITDA margin? | Oxford BioMedica's last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of Oxford BioMedica? | Current EBITDA multiple of Oxford BioMedica is 91.9x. |
| What is the current FCF of Oxford BioMedica? | Oxford BioMedica's last 12 months FCF is ($22M). |
| What is Oxford BioMedica's FCF margin? | Oxford BioMedica's last 12 months FCF margin is (9%). |
| What is the current EV/FCF multiple of Oxford BioMedica? | Current FCF multiple of Oxford BioMedica is (50.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.